Clinical Report: Permanent J-Code for Epioxa
Overview
Glaukos has received a permanent HCPCS J-code for Epioxa, effective July 1, 2026, which is expected to simplify billing and reimbursement for its corneal cross-linking therapy for keratoconus. This development may enhance payer acceptance and improve patient access to treatment.
Background
The introduction of a permanent J-code for Epioxa represents a significant advancement in the management of keratoconus, a condition that is often underdiagnosed and under-treated. The J-code will facilitate smoother reimbursement processes, potentially increasing the adoption of this innovative therapy among corneal specialists. Epioxa offers an incision-free alternative to traditional cross-linking procedures, which is crucial for improving patient outcomes.
Data Highlights
No numerical data available in the source material.
Key Findings
['Glaukos received a permanent HCPCS J-code (J2789) for Epioxa, effective July 1, 2026.', 'Epioxa is indicated for epithelium-on corneal collagen cross-linking in adults and pediatric patients aged 13 and older.', 'The therapy aims to reduce pain and streamline recovery compared to traditional epi-off cross-linking.', 'Common adverse reactions include conjunctival hyperemia, corneal haze, photophobia, punctate keratitis, eye pain, irritation, tearing, and transient reduction in visual acuity.', 'The J-code is expected to enhance payer acceptance and improve access for patients with keratoconus.']Clinical Implications
The establishment of a permanent J-code for Epioxa may lead to improved reimbursement workflows for healthcare providers, facilitating broader access to this innovative treatment. Clinicians should be aware of the potential for enhanced patient care through the adoption of this therapy, particularly for those with keratoconus.
Conclusion
The permanent J-code for Epioxa marks a pivotal moment in the treatment landscape for keratoconus, potentially improving access and reimbursement for patients. This development underscores the importance of innovative therapies in advancing patient care.
Related Resources & Content
- Glaukos Corporation, BusinessWire, 2026 -- Permanent J-Code for Epioxa
- Ophthalmology Management, 2026 -- Glaukos Launches EpioxaCareConnect
- Contact Lens Spectrum, 2026 -- Glaukos Announces Commercial Availability of Epioxa
- Ophthalmology Management, 2026 -- Corneal Crosslinking Reimbursement In Its Tenth Year
- Glaucoma Physician — Permanent J-code Assigned for iDose TR Recommendations
- HIGHLIGHTS OF PRESCRIBING INFORMATION
- AAO Corneal Ectasia Guideline Summary 2024 Preferred Practice Pattern
- Glaukos Corporation - Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
Based on findings from:
Permanent J-Code for Epioxa
The Ophthalmologist, 2026.
https://www.theophthalmologist.com/issues/2026/articles/april/permanent-j-code-for-epioxa/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
